Supplier News
Nexelis to Acquire ImmunXperts, an Immunogenicity and Immune-Oncology Testing Lab
The acquisition will expand Nexelis’ immunology testing expertise.
Absolute Antibody Launches New, High-Throughput Recombinant Antibody Production Service
The technology enables the rapid production of large numbers of recombinant antibodies at 80-mL scale.
ProBioGen, ImmunOs to Collaborate on Immunomodulators Using Transposase Technology
The partners will use ProBioGen’s DirectedLuck transposase technology to support development and large-scale manufacturing of ImmunOs’ biologics.
Eurofins DiscoverX Grants Bioassay Certification to VelaLabs
Eurofins DiscoverX partners with VelaLabs to enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions.
ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement
Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.
WuXi and Vir to Collaborate on Novel Coronavirus Treatment
The companies are entering into a development and manufacturing collaboration for the advancement and production of human monoclonal antibodies for the potential treatment of novel coronavirus.
Takeda Acquires PvP Biologics for up to $330 Million
Takeda announced the acquisition after the conclusion of a Phase 1 study of the investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease.
MabPlex Launches New 2000-L Cell Culture Production Lines
The expansion gives the company diversified capacity running cell production lines featuring Sartorius-brand 2000-L disposable bioreactors and now GE-brand 2000-L single-use bioreactors.
Dyadic Achieves G2 Human-Like Glycosylation Milestone
The company presented data on its G2 glycosylation studies at the 15th European Conference on Fungal Genetics in Rome on Feb. 19, 2020.
Treatment for XLH Receives Approval in Switzerland
Kyowa Kirin has announced that its treatment for X-linked hypophosphatemia (XLH), Crysvita (burisumab), has been approved by Swissmedic for use in adults, adolescents, and children (1 year and older).
Aprecia to Partner with Purdue University for 3D Pharmaceutical Printing Projects
Aprecia, which has an FDA-approved 3D-printed medication, will collaborate with Purdue’s College of Pharmacy to accelerate development in 3DP pharmaceuticals.
GSK and Immatics in $550-Million+ Pact to Develop Adoptive Cell Therapies
The companies aim to develop novel cell therapies for treating multiple cancers.
Audentes to Invest $109 Million into Gene Therapy Manufacturing Facility
The 135,000 square foot facility will be constructed over 18 months and is expected to be operational in 2021.
Sanofi Partners with BARDA for Novel Coronavirus Vaccine Development
Sanofi will use a recombinant DNA platform that produces a genetic match to proteins found on the surface of COVID-19 to formulate the vaccine.
WuXi Biologics Provides Update on Operations in Light of Coronavirus Outbreak
The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.
MilliporeSigma and ReForm Collaborate on Excipient Commercialization
The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.
Catalent and Zumutor Partner for Solid Tumor Treatment Manufacturing
Through the agreement, Catalent will offer process optimization and drug substance manufacturing services for the drug candidate at its Madison, WI site.
Catalent Appoints New Vice-President of Operations
Jim Walter will take on the role of vice-president of operations for Catalent’s Oral and Specialty Delivery business.
Hitachi Chemical Opens New Cell and Gene Therapy Manufacturing Facility
The new facility includes six classified environment rooms with space to expand.
Catalent to Acquire MaSTherCell Global for $315 Million
Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.
Horizon Discovery Licenses Knockout CHO Cell Line to NGM Biopharmaceuticals
The knockout CHO K1 cell line will be used to support biotherapeutic R&D across a range of therapeutic indications.
Evonetix, imec Partner on Chip-Based Technology Scale-Up
The partners will collaborate on developing scale-up chip-based technology to enable commercial-scale production of a third-generation DNA synthesis platform.
MilliporeSigma’s New Microbial Bioburden Testing System Offers Enhanced Results and Increased Productivity
The company’s new Milliflex Oasis System provides enhanced result reliability, increased productivity, and advanced traceability.
Otsuka, PhoreMost Team Up for Drug Discovery
Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.
Daiichi Sankyo Licenses ERS Genomics’ CRISPR Gene Editing Tech
The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.
Jones Packaging Becomes Jones Healthcare After 100 Years in Health and Wellness
The company announced it will be unveiling a new name, Jones Healthcare Group, and a new corporate logo as it celebrates 100 years in the health and wellness markets.
Vetter Combines Laboratory Portfolio into Single Site
The new 1800-m2 building houses more than 50 employees and features non-GMP laboratory space and a GMP analytical laboratory.
Lonza Expands Partnership with Rocket Pharmaceuticals for Childhood Disorder Treatment
Clinical manufacturing of the therapy will take place at Lonza's Houston, TX, and Netherlands cGMP manufacturing sites.
The Discovery Labs, Deerfield Management Create New CDMO and Invest $1.1 Billion in New Cell and Gene Therapy Facility
The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.
Vanrx Partners and G-CON Launch New Turnkey Facility
The fully integrated, pre-qualified, pre-installed aseptic filling facility can be shipped globally for drug development and the manufacturing of personalized medicines and clinical trial supplies.
